Furthermore, high expression of DILA1 in BC tissue was associated both with cyclin D1 overexpression and with poor prognosis in BC patients who received tamoxifen treatment, suggesting that DILA1 might be an interesting therapeutic target to downregulate cyclin D1 and reverse tamoxifen resistance in BC patients [197]. Here, MIR99AHG is linked to breast cancer.